Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M21,140Revenue $M16,326Net Margin (%)13.4Altman Z-Score2.3
Enterprise Value $M28,040EPS $4.0Operating Margin %14.5Piotroski F-Score6
P/E(ttm)9.6Beneish M-Score-2.8Pre-tax Margin (%)13.4Higher ROA y-yY
Price/Book2.610-y EBITDA Growth Rate %10.9Quick Ratio1.7Cash flow > EarningsY
Price/Sales1.35-y EBITDA Growth Rate %5.5Current Ratio2.3Lower Leverage y-yN
Price/Free Cash Flow27.1y-y EBITDA Growth Rate %-4.7ROA % (ttm)8.3Higher Current Ratio y-yY
Dividend Yield %5.4PEG2.2ROE % (ttm)27.0Less Shares Outstanding y-yN
Payout Ratio %66.0Shares Outstanding M546ROIC % (ttm)12.5Gross Margin Increase y-yY

Gurus Latest Trades with BAX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXVanguard Health Care Fund 2015-06-30 Buy 0.15%$34.81 - $39.3
($37.38)
$ 38.754%New holding1,945,220
BAXJoel Greenblatt 2015-06-30 Sold Out -0.13%$34.81 - $39.3
($37.38)
$ 38.754%Sold Out0
BAXFirst Eagle Investment 2015-06-30 Add0.06%$34.81 - $39.3
($37.38)
$ 38.754%Add 76507.82%842,686
BAXTweedy Browne 2015-06-30 Reduce-0.04%$34.81 - $39.3
($37.38)
$ 38.754%Reduce 0.81%2,543,966
BAXJohn Keeley 2015-06-30 Add0.01%$34.81 - $39.3
($37.38)
$ 38.754%Add 15.19%61,580
BAXKen Fisher 2015-06-30 Buy $34.81 - $39.3
($37.38)
$ 38.754%New holding3,652
BAXMario Gabelli 2015-06-30 Add$34.81 - $39.3
($37.38)
$ 38.754%Add 11.59%183,950
BAXRichard Pzena 2015-06-30 Add$34.81 - $39.3
($37.38)
$ 38.754%Add 0.04%5,030,632
BAXCharles Brandes 2015-06-30 Add$34.81 - $39.3
($37.38)
$ 38.754%Add 5.17%241,872
BAXJohn Rogers 2015-06-30 Reduce$34.81 - $39.3
($37.38)
$ 38.754%Reduce 1.59%61,951
BAXDavid Dreman 2015-06-30 Add$34.81 - $39.3
($37.38)
$ 38.754%Add 18.32%9,319
BAXRichard Pzena 2015-03-31 Add0.41%$36.39 - $39.82
($37.91)
$ 38.752%Add 27.49%5,028,418
BAXJoel Greenblatt 2015-03-31 Add0.13%$36.39 - $39.82
($37.91)
$ 38.752%Add 4622.98%244,934
BAXFirst Eagle Investment 2015-03-31 Reduce-0.12%$36.39 - $39.82
($37.91)
$ 38.752%Reduce 99.84%1,100
BAXDavid Dreman 2015-03-31 Add0.03%$36.39 - $39.82
($37.91)
$ 38.752%Add 124.77%7,876
BAXTweedy Browne 2015-03-31 Reduce-0.01%$36.39 - $39.82
($37.91)
$ 38.752%Reduce 0.29%2,564,814
BAXCharles Brandes 2015-03-31 Reduce-0.01%$36.39 - $39.82
($37.91)
$ 38.752%Reduce 3.40%229,981
BAXJohn Keeley 2015-03-31 Add0.01%$36.39 - $39.82
($37.91)
$ 38.752%Add 26.95%53,460
BAXMario Gabelli 2015-03-31 Reduce$36.39 - $39.82
($37.91)
$ 38.752%Reduce 4.66%164,850
BAXRichard Pzena 2014-12-31 Buy 1.5%$36.52 - $40.58
($38.95)
$ 38.75-1%New holding3,944,140
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Shapazian Carole JDirector 2015-05-22Sell1,533$67.68-42.75view
STROUCKEN ALBERT P LDirector 2015-04-27Sell4,830$71.06-45.47view
STORM KORNELIS J.Director 2015-04-27Sell4,830$71.05-45.46view
GAVIN JAMES R IIIDirector 2015-04-27Sell4,830$71.06-45.47view
HELLMAN PETER SDirector 2015-02-06Sell4,830$71.32-45.67view
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-48.26view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-49.66view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-49.56view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-49.01view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-47.92view

Quarterly/Annual Reports about BAX:

News about BAX:

Articles On GuruFocus.com
Baxalta Vs. AbbVie: Biopharma Spin-Off Battle Aug 20 2015 
Scott Black Sells Stakes in 10 Companies Aug 10 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Undervalued Baxalta Shares Target of Acquisition by Shire Plc Aug 05 2015 
Baxalta: A Rare Undervalued Biopharmaceutical Company Jul 23 2015 
John Rogers' Undervalued Stocks Trading With Low P/E Ratio Jul 14 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Live Off Your Monthly Dividend Portfolio Mar 19 2015 

More From Other Websites
[$$] Hedge Funds' Defensive Posture Limits Losses Aug 29 2015
Baxter International, Inc. Q2 Earnings, 2015 Aug 25 2015
5 Stocks Hedge Funds Loved in the Second Quarter Aug 21 2015
Baxter Expands Product Portfolio: Adds CEFAZOLIN Injection Aug 17 2015
Baxter International Inc (BAX) and T-Mobile US Inc (TMUS) Among Dan Loeb’s Top New Picks Aug 17 2015
BAXTER INTERNATIONAL INC Financials Aug 15 2015
Baxter and Water Street Announce FDA Approval of CEFAZOLIN 2 Gram Premix Aug 14 2015
Baxter and Water Street Announce FDA Approval of CEFAZOLIN 2 Gram Premix Aug 14 2015
Shire seen having wiggle room on price in $30 billion Baxalta battle Aug 13 2015
ICU Medical, Inc.: Leads amongst peers with strong fundamentals Aug 12 2015
Baxter Int'l. (BAX) Stock Price Target Raised at Barclays Aug 11 2015
Scott Black Sells Stakes in 10 Companies Aug 10 2015
St. Jude Medical, Inc. Earnings Q2*, 2015 Aug 10 2015
Baxter (BAX) is in Overbought Territory: What's Next? - Tale of the Tape Aug 10 2015
10-Q for Baxter International, Inc. Aug 09 2015
BAXTER INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
Basic materials M&A hits seven-year high buoyed by chemicals deals Aug 07 2015
Dan Loeb’s Third Point Amends Stake in Baxter International Inc (BAX) to 9.6% Aug 07 2015
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

Sww
ReplySww - 1 year ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK